Skip to main content
Top
Published in: BMC Cancer 1/2007

Open Access 01-12-2007 | Research article

Disease-specific survival for limited-stage small-cell lung cancer affected by statistical method of assessment

Authors: Patricia Tai, Judith-Anne W Chapman, Edward Yu, Dennie Jones, Changhong Yu, Fei Yuan, Lee Sang-Joon

Published in: BMC Cancer | Issue 1/2007

Login to get access

Abstract

Background

In general, prognosis and impact of prognostic/predictive factors are assessed with Kaplan-Meier plots and/or the Cox proportional hazard model. There might be substantive differences from the results using these models for the same patients, if different statistical methods were used, for example, Boag log-normal (cure-rate model), or log-normal survival analysis.

Methods

Cohort of 244 limited-stage small-cell lung cancer patients, were accrued between 1981 and 1998, and followed to the end of 2005. The endpoint was death with or from lung cancer, for disease-specific survival (DSS). DSS at 1-, 3- and 5-years, with 95% confidence limits, are reported for all patients using the Boag, Kaplan-Meier, Cox, and log-normal survival analysis methods. Factors with significant effects on DSS were identified with step-wise forward multivariate Cox and log-normal survival analyses. Then, DSS was ascertained for patients with specific characteristics defined by these factors.

Results

The median follow-up of those alive was 9.5 years. The lack of events after 1966 days precluded comparison after 5 years. DSS assessed by the four methods in the full cohort differed by 0–2% at 1 year, 0–12% at 3 years, and 0–1% at 5 years. Log-normal survival analysis indicated DSS of 38% at 3 years, 10–12% higher than with other methods; univariate 95% confidence limits were non-overlapping. Surgical resection, hemoglobin level, lymph node involvement, and superior vena cava (SVC) obstruction significantly impacted DSS. DSS assessed by the Cox and log-normal survival analysis methods for four clinical risk groups differed by 1–6% at 1 year, 15–26% at 3 years, and 0–12% at 5 years; multivariate 95% confidence limits were overlapping in all instances.

Conclusion

Surgical resection, hemoglobin level, lymph node involvement, and superior vena cava (SVC) obstruction all significantly impacted DSS. Apparent DSS for patients was influenced by the statistical methods of assessment. This would be clinically relevant in the development or improvement of clinical management strategies.
Appendix
Available only for authorised users
Literature
1.
go back to reference Cox DR: Partial likelihood. Biometrika. 1975, 62: 269-276. 10.1093/biomet/62.2.269.CrossRef Cox DR: Partial likelihood. Biometrika. 1975, 62: 269-276. 10.1093/biomet/62.2.269.CrossRef
2.
go back to reference Frankel P, Longmate J: Parametric models for accelerated and long-term survival: a comment on proportional hazards. Stat Med. 2002, 21: 3279-3289. 10.1002/sim.1273.CrossRefPubMed Frankel P, Longmate J: Parametric models for accelerated and long-term survival: a comment on proportional hazards. Stat Med. 2002, 21: 3279-3289. 10.1002/sim.1273.CrossRefPubMed
3.
go back to reference Pierce DA, Stewart WH, Kopecky KJ: Distribution-free regression analysis of grouped survival data. Biometrics. 1979, 35: 785-793. 10.2307/2530110.CrossRefPubMed Pierce DA, Stewart WH, Kopecky KJ: Distribution-free regression analysis of grouped survival data. Biometrics. 1979, 35: 785-793. 10.2307/2530110.CrossRefPubMed
4.
go back to reference Farewell VT: The use of mixture models for the analysis of survival data with long-term survivors. Biometrics. 1982, 38: 1041-1046. 10.2307/2529885.CrossRefPubMed Farewell VT: The use of mixture models for the analysis of survival data with long-term survivors. Biometrics. 1982, 38: 1041-1046. 10.2307/2529885.CrossRefPubMed
5.
go back to reference Yin G, Ibrahim JG: Cure rate models: a unified approach. The Canadian Journal of Statistics. 2005, 33: 559-570.CrossRef Yin G, Ibrahim JG: Cure rate models: a unified approach. The Canadian Journal of Statistics. 2005, 33: 559-570.CrossRef
6.
go back to reference Gamel JW, McLean IW: A stable, multivariate extension of the log-normal survival model. Comput Biomed Res. 1994, 27: 148-155. 10.1006/cbmr.1994.1014.CrossRefPubMed Gamel JW, McLean IW: A stable, multivariate extension of the log-normal survival model. Comput Biomed Res. 1994, 27: 148-155. 10.1006/cbmr.1994.1014.CrossRefPubMed
7.
go back to reference Boag JW: Maximum likelihood estimates of the proportion of patients cured by cancer therapy. J R Stat Soc B. 1949, 11: 15-44. Boag JW: Maximum likelihood estimates of the proportion of patients cured by cancer therapy. J R Stat Soc B. 1949, 11: 15-44.
8.
go back to reference Ciampi A, Chapman J, Hogg S, Thiffault J: GENCOV: a Fortran program that generates randomly censored survival data with covariates. Computer Methods and Programs in Biomedicine. 1989, 29: 51-57. 10.1016/0169-2607(89)90090-4.CrossRefPubMed Ciampi A, Chapman J, Hogg S, Thiffault J: GENCOV: a Fortran program that generates randomly censored survival data with covariates. Computer Methods and Programs in Biomedicine. 1989, 29: 51-57. 10.1016/0169-2607(89)90090-4.CrossRefPubMed
9.
go back to reference Hallett D, Chapman JW, Gamel JW, McLean IW: Estimation of "cure" rate for intraocular melanoma. Proc Am Assoc Cancer Res. 1999, 40: 43- Hallett D, Chapman JW, Gamel JW, McLean IW: Estimation of "cure" rate for intraocular melanoma. Proc Am Assoc Cancer Res. 1999, 40: 43-
10.
go back to reference Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, Parker HL: Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol. 2001, 19: 980-991.PubMed Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, Parker HL: Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol. 2001, 19: 980-991.PubMed
11.
go back to reference Royston P: The lognormal distribution as a model for survival time in cancer, with an emphasis on prognostic factors. Stat Neerlandica. 2001, 55: 89-104. 10.1111/1467-9574.00158.CrossRef Royston P: The lognormal distribution as a model for survival time in cancer, with an emphasis on prognostic factors. Stat Neerlandica. 2001, 55: 89-104. 10.1111/1467-9574.00158.CrossRef
12.
go back to reference Tai P, Tonita J, Yu E, Skarsgard D: Twenty-year follow-up study of long-term survival of limited-stage small-cell lung cancer and overview of prognostic and treatment factors. Int J Radiation Oncology Biol Phys. 2003, 56: 626-633. 10.1016/S0360-3016(03)00070-1.CrossRef Tai P, Tonita J, Yu E, Skarsgard D: Twenty-year follow-up study of long-term survival of limited-stage small-cell lung cancer and overview of prognostic and treatment factors. Int J Radiation Oncology Biol Phys. 2003, 56: 626-633. 10.1016/S0360-3016(03)00070-1.CrossRef
13.
go back to reference Overduin S: Use of the lognormal distribution for survival data: inference and robustness. M.Sc. thesis supervised by Stephens MA, Simon Fraser University, Canada. 2004 Overduin S: Use of the lognormal distribution for survival data: inference and robustness. M.Sc. thesis supervised by Stephens MA, Simon Fraser University, Canada. 2004
14.
go back to reference Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958, 53: 457-481. 10.2307/2281868.CrossRef Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958, 53: 457-481. 10.2307/2281868.CrossRef
15.
go back to reference McCready DR, Chapman JA, Hanna WM, Kahn HJ, Murray D, Fish EB, Trudeau ME, Andrulis IL, Lickley HL: Factors affecting distant disease-free survival for primary invasive breast cancer: use of a log-normal survival model. Ann Surg Oncol. 2000, 7: 416-426. 10.1007/s10434-000-0416-z.CrossRefPubMed McCready DR, Chapman JA, Hanna WM, Kahn HJ, Murray D, Fish EB, Trudeau ME, Andrulis IL, Lickley HL: Factors affecting distant disease-free survival for primary invasive breast cancer: use of a log-normal survival model. Ann Surg Oncol. 2000, 7: 416-426. 10.1007/s10434-000-0416-z.CrossRefPubMed
16.
go back to reference Chapman JA, Lickley HL, Trudeau ME, Hanna WM, Kahn HJ, Murray D, Sawka CA, Mobbs BG, McCready DR, Pritchard KI: Ascertaining prognosis for breast cancer in node-negative patients with innovative survival analysis. Breast J. 2006, 12: 37-47. 10.1111/j.1075-122X.2006.00183.x.CrossRefPubMed Chapman JA, Lickley HL, Trudeau ME, Hanna WM, Kahn HJ, Murray D, Sawka CA, Mobbs BG, McCready DR, Pritchard KI: Ascertaining prognosis for breast cancer in node-negative patients with innovative survival analysis. Breast J. 2006, 12: 37-47. 10.1111/j.1075-122X.2006.00183.x.CrossRefPubMed
17.
go back to reference Brenner DJ, Hall EJ: The radiotherapy workbench. 1992, Columbia, MD: Radio Programmes Brenner DJ, Hall EJ: The radiotherapy workbench. 1992, Columbia, MD: Radio Programmes
18.
go back to reference Hall EJ: Time, dose, and fractionation in radiotherapy. Radiobiology for the radiologist. Edited by: Hall EJ. 1994, Philadelphia:JB Lippincott, 223-225. 4 Hall EJ: Time, dose, and fractionation in radiotherapy. Radiobiology for the radiologist. Edited by: Hall EJ. 1994, Philadelphia:JB Lippincott, 223-225. 4
19.
go back to reference Lawless JF: Statistical Models and Methods for Lifetime Data. 2003, Wiley series in Probability and Statistics, John Wiley & Sons, Inc., Hoboken, New Jersey, 211, 342, 358-2 Lawless JF: Statistical Models and Methods for Lifetime Data. 2003, Wiley series in Probability and Statistics, John Wiley & Sons, Inc., Hoboken, New Jersey, 211, 342, 358-2
20.
go back to reference BMDP Statistical Software, PC Dynamic 7.0. 1993, Saugua, MA: Statistical Solutions Ltd BMDP Statistical Software, PC Dynamic 7.0. 1993, Saugua, MA: Statistical Solutions Ltd
21.
go back to reference Bremnes RM, Sundstrom S, Aasebo U, Kaasa S, Hatlevoll R, Aamdal S, Norweigian Lung Cancer Study Group: The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer. 2003, 39: 303-313. 10.1016/S0169-5002(02)00508-1.CrossRefPubMed Bremnes RM, Sundstrom S, Aasebo U, Kaasa S, Hatlevoll R, Aamdal S, Norweigian Lung Cancer Study Group: The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer. 2003, 39: 303-313. 10.1016/S0169-5002(02)00508-1.CrossRefPubMed
22.
go back to reference Ando S, Suzuki M, Yamamoto N, Iida T, Kimura H: The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer. Anticancer Res. 2004, 24: 1941-1946.PubMed Ando S, Suzuki M, Yamamoto N, Iida T, Kimura H: The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer. Anticancer Res. 2004, 24: 1941-1946.PubMed
23.
go back to reference Oshita F, Kameda Y, Hamanaka N, Saito H, Yamada K, Noda K, Mitsuda A: High expression of integrin beta1 and p53 is a greater poor prognostic factor than clinical stage in small-cell lung cancer. Am J Clin Oncol. 2004, 27: 215-219. 10.1097/01.COC.0000054894.64867.80.CrossRefPubMed Oshita F, Kameda Y, Hamanaka N, Saito H, Yamada K, Noda K, Mitsuda A: High expression of integrin beta1 and p53 is a greater poor prognostic factor than clinical stage in small-cell lung cancer. Am J Clin Oncol. 2004, 27: 215-219. 10.1097/01.COC.0000054894.64867.80.CrossRefPubMed
24.
go back to reference Oshita F, Kameda Y, Ikehara M, Tanaka G, Yamada K, Nomura I, Noda K, Shotsu A, Fujita A, Arai H, Ito H, Nakayama H, Mitsuda A: Increased expression of integrin beta1 is a poor prognostic factor in small-cell lung cancer. Anticancer Res. 2002, 22: 1065-1070.PubMed Oshita F, Kameda Y, Ikehara M, Tanaka G, Yamada K, Nomura I, Noda K, Shotsu A, Fujita A, Arai H, Ito H, Nakayama H, Mitsuda A: Increased expression of integrin beta1 is a poor prognostic factor in small-cell lung cancer. Anticancer Res. 2002, 22: 1065-1070.PubMed
25.
go back to reference Blackhall FH, Pintilie M, Michael M, Leighl N, Feld R, Tsao MS, Shepherd FA: Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. Clin Cancer Res. 2003, 9: 2241-2247.PubMed Blackhall FH, Pintilie M, Michael M, Leighl N, Feld R, Tsao MS, Shepherd FA: Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. Clin Cancer Res. 2003, 9: 2241-2247.PubMed
Metadata
Title
Disease-specific survival for limited-stage small-cell lung cancer affected by statistical method of assessment
Authors
Patricia Tai
Judith-Anne W Chapman
Edward Yu
Dennie Jones
Changhong Yu
Fei Yuan
Lee Sang-Joon
Publication date
01-12-2007
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2007
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-7-31

Other articles of this Issue 1/2007

BMC Cancer 1/2007 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine